glp-1 marketing CPG Consumer Trends | Retail Strategy GLP-1 Receptor Agonist Market Size

When biosimilar entry finally came, it was not a cliff

Patients often experience steady, progressive weight loss during this phase

Proceedings of the National Academy of Sciences , 110 (22), 90669071

A separate meta-analysis including 117 RCTs with 221 364 participants revealed that albiglutide (RR = 0.29

As long as a drug is under patent, the original manufacturer has exclusive rights to sell it, keeping prices high

For example, in a clinical study comparing exenatide BID (Byetta) and exenatide QW (Bydureon), it was found that after 14 weeks of administration, Byetta still induced significant retardation of gastric emptying, while Bydureon had little effect on gastric mobility [106]